NCT Number: NCT00413985
Post Discharge Human Milk Fortifier in Preterm Infants
The purpose of this study is to determine whether low birth weight (LBW) infants fed human milk (HM)supplemented with a specially designed powdered human milk fortifier until 12 weeks after hospital discharge will have better growth and neurodevelopment than infants fed HM alone.
Looking for future studies?
Notify MeKey information
Age range
1 day–4 month
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2
Primary location
The Credit Valley Hospital, Mississauga, Ontario, Canada
About this study
Consensus exists in the literature that a significant proportion of low birth weight (LBW, <1800 g) infants leave hospital with overt signs of under-nutrition (eg. growth retardation). Recent evidence from randomized control trials suggest that provision of nutrient-enriched feeding to formula-fed premature infants after hospital discharge improves their growth, accretion of lean body mass and bone mineral content compared to infants fed a standard term formula. While available data suggest an advantage of human milk feeding after hospital discharge, experimental evidence on which to base guidelines to enrich, or not to enrich, human milk (HM) are notably absent.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Birth Weight between 750-1800 g
- Gestational Age at birth between 26 and 32 weeks
- Singleton or twin birth (for twins to be eligible, both must meet eligibility criteria)
- Small for Gestational age or appropriate for gestational age
- ≥ 80% energy received from human milk in the previous three days
- ≥ 25% of human milk consumed orally in the previous three days
- Mother agrees to exclusively feed her infant human nilk after discharge
- If so randomized, parents agree to supplement ~1/2 or the human milk provided to her infant as powdered human milk fortifier for 12 weeks after hospital discharge
- Subject's parents have voluntarily signed an informed consent form
Exclusion criteria
- Serious congenital or chromosomal anomalies that will affect growth
- Grade III or IV periventricular/intraventricular hemorrhage
- Received steroids within 14 days o randomization
- Asphyxia (hypoxia or ischemia) es evident by severe and permanent neurological data
- Maternal incapacity, including maternal cocaine or alcohol abuse dring pregnancy, or concurrent, or mother or infant has tested positive for HIV
- Principal residence of study family outside GTA
- Mother unable to verbally communicate in English
- A single feeding must be fortified > 24 kcal/oz or >50% of feeds need to be fortified
Treatment and study plan
Primary outcomes
-
Growth (weight, length and head circumference)
-
Body composition (fat-free mass, whole body mineral content, fat mass
-
Milk consumption
-
Estimated energy and nutrient intakes
-
Duration/exclusivity of breastfeeding
-
Morbidity (serious adverse events, hospital re-admissions)
-
Development (mental, motor, visual and language)
Sponsors and collaborators
Lead sponsor
The Hospital for Sick Children
Other
Collaborators
- Canadian Institutes of Health Research (CIHR)
Registry information
Official study title
Growth and Development in Preterm Infants Fed Human Milk Containing a Powdered Human Milk Fortifier (HMF) Post Hospital Discharge
Important dates
- Study start
- 2004
- Primary completion
- 2007
- First posted
- Dec 20, 2006
- Registry last updated
- Dec 31, 2013
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Global Survey on Newborns' HOspitalisation and Parental Experiences - the HOPE Study
NCT06827028
Anxiety, Anxiety Disorders
Munich, Bavaria, Germany
View Trial DetailsHousehold Air Pollution and Health: A Multi-country LPG Intervention Trial
NCT02944682
Arterial Occlusive Diseases, Arteriosclerosis
Guatemala City, Departamento de Guatemala, Guatemala
View Trial DetailsLaparotomy vs. Drainage for Infants With Necrotizing Enterocolitis
NCT01029353
Digestive System Diseases, Enterocolitis
Birmingham, Alabama, United States
View Trial DetailsReducing Anemia in Pregnancy in India: the RAPIDIRON Trial
NCT05358509
Anemia, Anemia of Pregnancy
Bagalkot, Karnataka, India
View Trial Details